| 产品描述: | HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active HDAC6 inhibitor with an IC50 of 0.019 μM. HDAC6-IN-13 also inhibits HDAC1, HDAC2 and HDAC3 with IC50s of 1.53, 2.06 and 1.03 μM, respectively. HDAC6-IN-13 shows significant BBB permeability and anti-inflammatory activity. |
| 靶点: |
HDAC6:0.019 μM (IC50); HDAC3:1.03 μM (IC50); HDAC1:1.53 μM (IC50); HDAC2:2.06 μM (IC50) |
| 体外研究: |
HDAC6-IN-13 (Compound 35m) (0.1-1 μM; 24 h) is highly selective toward HDAC6 versus class I HDACs. HDAC6-IN-13 is a slow-on and slow-off tight-binding HDAC6 inhibitor, while exhibits fast-on properties for HDAC1, 2, and 3. HDAC6-IN-13 (5-20 μM; 8 h) shows anti-inflammatory activity in vitro. |
| 体内研究: |
HDAC6-IN-13 (Compound 35m) (20 mg/kg; p.o. and i.p.; once) displays a remarkable inhibition in LPS-induced inflammation in mice. HDAC6-IN-13 (20 mg/kg; p.o.; once) shows very high oral bioavailability (F% = 93.4%) and significant BBB permeability in mi |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.699 ml |
13.497 ml |
26.994 ml |
| 5 mM |
0.54 ml |
2.699 ml |
5.399 ml |
| 10 mM |
0.27 ml |
1.35 ml |
2.699 ml |
| 50 mM |
0.054 ml |
0.27 ml |
0.54 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |